Zydus Lifesciences Croissance future

Future contrôle des critères 0/6

Zydus Lifesciences devrait augmenter ses bénéfices et son chiffre d'affaires de 0.6% et de 6.6% par an respectivement. Le BPA devrait croître de de 0.7% par an. Le rendement des capitaux propres devrait être 16% dans 3 ans.

Informations clés

0.6%

Taux de croissance des bénéfices

0.7%

Taux de croissance du BPA

Pharmaceuticals croissance des bénéfices	17.9%
Taux de croissance des recettes	6.6%
Rendement futur des capitaux propres	16.0%
Couverture par les analystes	Good
Dernière mise à jour	26 Nov 2024

Mises à jour récentes de la croissance future

Zydus Lifesciences Limited (NSE:ZYDUSLIFE) Just Reported Earnings, And Analysts Cut Their Target Price

Nov 15

Zydus Lifesciences Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Aug 14

Recent updates

Zydus Lifesciences Limited (NSE:ZYDUSLIFE) Just Reported Earnings, And Analysts Cut Their Target Price

Nov 15

Here's Why We Think Zydus Lifesciences (NSE:ZYDUSLIFE) Is Well Worth Watching

Sep 14

Zydus Lifesciences Limited's (NSE:ZYDUSLIFE) Business And Shares Still Trailing The Market

Aug 30

Zydus Lifesciences Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Aug 14

Zydus Lifesciences Limited's (NSE:ZYDUSLIFE) CEO Compensation Is Looking A Bit Stretched At The Moment

Aug 03

Zydus Lifesciences (NSE:ZYDUSLIFE) Will Pay A Smaller Dividend Than Last Year

Jul 19

Zydus Lifesciences' (NSE:ZYDUSLIFE) Shareholders Will Receive A Smaller Dividend Than Last Year

Jul 05

Earnings Not Telling The Story For Zydus Lifesciences Limited (NSE:ZYDUSLIFE) After Shares Rise 28%

Feb 28

Analyst Estimates: Here's What Brokers Think Of Zydus Lifesciences Limited (NSE:ZYDUSLIFE) After Its Third-Quarter Report

Feb 12

Zydus Lifesciences (NSE:ZYDUSLIFE) Could Easily Take On More Debt

Dec 27

Here's Why Zydus Lifesciences (NSE:ZYDUSLIFE) Has Caught The Eye Of Investors

Dec 06

With EPS Growth And More, Zydus Lifesciences (NSE:ZYDUSLIFE) Makes An Interesting Case

Aug 23

Zydus Lifesciences' (NSE:ZYDUSLIFE) Dividend Will Be Increased To ₹6.00

Jul 17

We Think Zydus Lifesciences (NSE:ZYDUSLIFE) Can Stay On Top Of Its Debt

Jul 15

Zydus Lifesciences' (NSE:ZYDUSLIFE) Upcoming Dividend Will Be Larger Than Last Year's

Jun 24

Zydus Lifesciences (NSE:ZYDUSLIFE) Is Increasing Its Dividend To ₹6.00

Jun 10

Zydus Lifesciences' (NSE:ZYDUSLIFE) Dividend Will Be Increased To ₹6.00

May 21

Zydus Lifesciences (NSE:ZYDUSLIFE) Seems To Use Debt Quite Sensibly

Feb 15

Prévisions de croissance des bénéfices et des revenus

NSEI:ZYDUSLIFE - Estimations futures des analystes et données financières antérieures (INR Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
3/31/2027	253,883	43,016	40,242	49,706	26
3/31/2026	242,802	46,332	41,349	49,444	30
3/31/2025	227,180	44,569	32,198	42,481	31
9/30/2024	214,835	42,777	31,783	45,938	N/A
6/30/2024	206,153	41,685	N/A	N/A	N/A
3/31/2024	195,474	38,365	23,213	32,279	N/A
12/31/2023	190,241	29,562	N/A	N/A	N/A
9/30/2023	187,760	28,109	28,078	37,726	N/A
6/30/2023	184,127	25,262	N/A	N/A	N/A
3/31/2023	172,374	19,649	16,579	26,888	N/A
12/31/2022	164,335	20,785	N/A	N/A	N/A
9/30/2022	157,110	19,629	8,934	20,209	N/A
6/30/2022	153,361	21,710	N/A	N/A	N/A
3/31/2022	151,099	22,416	10,146	21,045	N/A
12/31/2021	157,609	23,267	N/A	N/A	N/A
9/30/2021	157,389	23,269	17,283	28,059	N/A
6/30/2021	156,130	22,600	N/A	N/A	N/A
3/31/2021	144,035	22,016	24,399	32,939	N/A
12/31/2020	150,076	18,465	N/A	N/A	N/A
9/30/2020	148,501	16,932	18,757	27,798	N/A
6/30/2020	143,967	13,270	N/A	N/A	N/A
3/31/2020	142,531	11,766	20,274	29,315	N/A
12/31/2019	142,338	12,448	N/A	N/A	N/A
9/30/2019	141,736	13,816	26,553	34,629	N/A
6/30/2019	137,682	16,919	N/A	N/A	N/A
3/31/2019	131,656	18,488	2,245	12,819	N/A
12/31/2018	126,706	19,954	N/A	N/A	N/A
9/30/2018	123,526	20,305	N/A	N/A	N/A
6/30/2018	126,133	21,168	N/A	N/A	N/A
3/31/2018	119,049	17,946	N/A	9,193	N/A
12/31/2017	111,691	15,705	N/A	N/A	N/A
9/30/2017	102,206	13,511	N/A	N/A	N/A
6/30/2017	93,397	12,277	N/A	N/A	N/A
3/31/2017	93,765	14,904	N/A	13,117	N/A
12/31/2016	97,494	11,323	N/A	N/A	N/A
9/30/2016	97,971	12,812	N/A	N/A	N/A
6/30/2016	97,221	14,186	N/A	N/A	N/A
3/31/2016	94,268	19,339	N/A	18,935	N/A
12/31/2015	95,901	14,843	N/A	N/A	N/A
9/30/2015	92,453	13,766	N/A	N/A	N/A
6/30/2015	89,795	12,638	N/A	N/A	N/A
3/31/2015	86,513	11,506	N/A	9,936	N/A
12/31/2014	82,955	10,394	N/A	N/A	N/A
9/30/2014	79,777	9,435	N/A	N/A	N/A
6/30/2014	76,165	8,488	N/A	N/A	N/A
3/31/2014	72,034	8,036	N/A	9,028	N/A
12/31/2013	68,204	8,266	N/A	N/A	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de ZYDUSLIFE ( 0.6% par an) est inférieure au taux d'épargne ( 6.7% ).

Bénéfices vs marché: Les bénéfices de ZYDUSLIFE ( 0.6% par an) devraient croître plus lentement que le marché Indian ( 17.9% par an).

Croissance élevée des bénéfices: Les bénéfices de ZYDUSLIFE devraient augmenter, mais pas de manière significative.

Chiffre d'affaires vs marché: Le chiffre d'affaires de ZYDUSLIFE ( 6.6% par an) devrait croître plus lentement que le marché de Indian ( 10.4% par an).

Croissance élevée des revenus: Le chiffre d'affaires de ZYDUSLIFE ( 6.6% par an) devrait croître plus lentement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Le retour sur capitaux propres de ZYDUSLIFE devrait être faible dans 3 ans ( 16 %).

Zydus Lifesciences Croissance future

Future contrôle des critères 0/6

Informations clés

Mises à jour récentes de la croissance future

Zydus Lifesciences Limited (NSE:ZYDUSLIFE) Just Reported Earnings, And Analysts Cut Their Target Price

Zydus Lifesciences Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Price target increased by 8.1% to ₹1,145

Consensus EPS estimates increase by 10%

Price target increased by 9.2% to ₹925

Price target increased by 9.3% to ₹753

Recent updates

Zydus Lifesciences Limited (NSE:ZYDUSLIFE) Just Reported Earnings, And Analysts Cut Their Target Price

New major risk - Revenue and earnings growth

Second quarter 2025 earnings: EPS misses analyst expectations

Zydus Lifesciences Limited to Report Q2, 2025 Results on Nov 12, 2024

Zydus Lifesciences Limited Receives in Principle Acceptability from World Health Organization for Zyvac Tcv

Zydus Lifesciences Limited Receives Final Approval from USFDA for Fludrocortisone Acetate Tablets USP, 0.1 Mg

Zydus Lifesciences Limited and ICMR Initiate A Phase 2 Proof-Of-Concept Trial of Desidustat in Patients with Sickle Cell Disease

Zydus Lifesciences Limited Receives Final Approval from USFDA for Paliperidone Extended-Release Tablets

Zydus Receives Tentative Approval from USFDA for Enzalutamide Tablets, 40 Mg and 80 Mg

Here's Why We Think Zydus Lifesciences (NSE:ZYDUSLIFE) Is Well Worth Watching

Zydus Lifesciences Limited's (NSE:ZYDUSLIFE) Business And Shares Still Trailing The Market

Zydus Lifesciences Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Price target increased by 8.1% to ₹1,145

Zydus Lifesciences Limited Approves Final Dividend for the Financial Year Ended on March 31, 2024

Zydus Lifesciences Limited's (NSE:ZYDUSLIFE) CEO Compensation Is Looking A Bit Stretched At The Moment

Zydus Lifesciences Limited Receives Final Approval from the United States Food and Drug Administration to Market Valsartan Tablets USP, 40 Mg, 80 Mg, 160 Mg and 320 Mg (USRLD: Diovan® Tablets)

Zydus Lifesciences Limited Receives Approval from COFEPRIS of Mexico to Market Bhava

Upcoming dividend of ₹3.00 per share

Zydus Lifesciences (NSE:ZYDUSLIFE) Will Pay A Smaller Dividend Than Last Year

Zydus Lifesciences Limited to Report Q1, 2025 Results on Aug 09, 2024

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Zydus Lifesciences' (NSE:ZYDUSLIFE) Shareholders Will Receive A Smaller Dividend Than Last Year

Zydus Receives Tentative Approval from Usfda for Azilsartan Medoxomil Tablets, 40 Mg and 80 Mg

Zydus Lifesciences (NSE:ZYDUSLIFE) Will Pay A Smaller Dividend Than Last Year

Zydus Lifesciences (NSE:ZYDUSLIFE) Could Easily Take On More Debt

Zydus Lifesciences (NSE:ZYDUSLIFE) Will Pay A Smaller Dividend Than Last Year

Consensus EPS estimates increase by 10%

Dividend reduced to ₹3.00

Price target increased by 9.2% to ₹925

Zydus Lifesciences Limited, Annual General Meeting, Aug 09, 2024

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Zydus Lifesciences Limited Proposes Final Dividend for the Financial Year Ended on March 31, 2024, Payable on or After August 13, 2024

Zydus Lifesciences Limited Announces Completion of Enrolment for EPICS IIITM Phase 2B/3 Trial Evaluating Saroglitazar Mg in Treatment of Primary Biliary Cholangitis

Zydus Lifesciences Limited Receives Final Approval from USFDA for Dapsone Gel, 7.5%

Bayer Pharmaceuticals Pvt. Ltd. agreed to acquire the remaining 24.99998% stake in Bayer Zydus Pharma Private Limited for INR 2.82 billion.

Zydus Lifesciences Limited Launches Mirabegron Extended-Release Tablets in the U.S

Insider recently sold ₹833k worth of stock

Does Zydus Lifesciences (NSE:ZYDUSLIFE) Deserve A Spot On Your Watchlist?

Earnings Not Telling The Story For Zydus Lifesciences Limited (NSE:ZYDUSLIFE) After Shares Rise 28%

Price target increased by 9.3% to ₹753

Analyst Estimates: Here's What Brokers Think Of Zydus Lifesciences Limited (NSE:ZYDUSLIFE) After Its Third-Quarter Report

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Zydus Receives Tentative Approval from the USFDA for Dexamethasone Tablets USP, 1 mg

Zydus Lifesciences Limited Receives Final Approvals from the United States Food and Drug Administration to Manufacture and Market Dexamethasone Tablets USP, 2 Mg

Zydus Lifesciences Launches RexigoTM, the Oral Once-A-Day Pill for Advanced Prostate Cancer Patients in India

Zydus Lifesciences Limited Receives Final Approval from the USFDA for Gabapentin Tablets (Once-Daily), 300 Mg and 600 Mg

Zydus Lifesciences Limited Receives Final Approvals from the United States Food and Drug Administration for Pimavanserin Capsules, 34 Mg and Pimavanserin Tablets,10 Mg

Zydus Lifesciences (NSE:ZYDUSLIFE) Could Easily Take On More Debt

Zydus Lifesciences Limited Zydus Receives Approval from USFDA to Initiate Phase II Clinical Trial of ZYIL1 in Patients with Parkinson's Disease

Zydus Lifesciences Limited Receives Final Approval from the USFDA for Cyclophosphamide Capsules USP, 25 Mg and 50 Mg

Here's Why Zydus Lifesciences (NSE:ZYDUSLIFE) Has Caught The Eye Of Investors

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Zydus Lifesciences Initiates Phase II Clinical Trial of ZYIL1

Zydus Lifesciences Limited Receives USFDA Approval for ZITUVIO™ to Treat Adult Patients with Type 2 Diabetes Mellitus

Zydus Lifesciences Limited Appoints Mr. Punit Patel as President and CEO to Lead Its Business Operations in North America

Zydus Receives Final Approval from the USFDA for Clindamycin Phosphate Gel USP, 1%

Zydus Receives Final Approval from the USFDA for Norelgestromin and Ethinyl Estradiol Transdermal System, 150 Mcg/35 Mcg Per Day

Zydus Lifesciences Limited Receives Final Approval from the United States Food and Drug Administration for Zinc Sulfate Injection USP, 10 mg/10 ml (3 mg/L) Pharmacy Bulk Package Vials

With EPS Growth And More, Zydus Lifesciences (NSE:ZYDUSLIFE) Makes An Interesting Case

Consensus EPS estimates increase by 12%

Price target increased by 14% to ₹627

Zydus Lifesciences Limited Approves Final Dividend for the Financial Year Ended on March 31, 2023

Zydus Lifesciences Limited (NSEI:ZYDUSLIFE) completed the acquisition of Active pharmaceutical ingredients arm of Watson Pharma from Watson Pharma.

Zydus Lifesciences Limited Announces Resignation of Rashmin Shah as President-Special Projects

Upcoming dividend of ₹6.00 per share at 1.0% yield

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Zydus Lifesciences' (NSE:ZYDUSLIFE) Dividend Will Be Increased To ₹6.00

Zydus Lifesciences Limited to Report Q3, 2024 Results on Feb 14, 2024

We Think Zydus Lifesciences (NSE:ZYDUSLIFE) Can Stay On Top Of Its Debt